Jim Cramer's Mad Dash: Regeneron to $400; Conn's a No-Touch

NEW YORK (TheStreet) -- On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, was very excited about Regeneron's (REGN) new cholesterol drug, Alirocumab. 

The company's anti-cholesterol drug is an alternative to statin and reduces the risk of strokes. Regeneron is partnered with Sanofi (SNY) for Alirocumab. 

The stock is breaking out, Cramer said, adding that Credit Suisse suggests it can go to $400 per share. 

"It's a very big win for Regeneron. It could be a multi-billion market," he said. 

Turning to Conn's (CONN) , Cramer noted that the stock is plummeting -- down over 30%. Management expressed concern that customers would not be paying Conn's the money it is owed. 

Investors want exposure to domestic retailers to protect themselves from geopolitical risks, Cramer said, but not all domestic retailers are created equal. 

He concluded that he is not a buyer of Conn's following the selloff, because a lot of investors still want to get out of the stock. 

-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

2 More Reasons to Sell All Your Stocks and Run Away

2 More Reasons to Sell All Your Stocks and Run Away

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast